你所在的位置: 首页 > 正文

数以亿元只为了开发一款新药,这个烧钱的健康行业居然火了?

2019-07-16 点击:1988
凯发国际平

Pre-IPO is valued at 2.15 billion yuan, and another biotechnology company has a successful board. The reporter learned from the column of the official website of the Shanghai Stock Exchange that the application for the science and technology board of Chengdu Pioneer Pharmaceutical Development Co. Ltd. was accepted on July 9. The company plans to raise 660 million yuan in the science and technology board.

It is understood that the company's specific business includes DEL screening services, DEL library customization services, chemical synthesis of new drug research and development projects, etc. in general, is the early drug discovery, to help the development of new drugs, innovative drugs. Investing in the research and development of new drugs, this company has invested tens of millions of yuan in research and development expenses.

Although the investment is high and the payback period is relatively long, the reporter found that more and more companies are beginning to join the drug R&D outsourcing service and play the game of the new drug market in the future.

RVo4cVC2aICFio

New drug research leads capital focus

The reporter learned from the company's prospectus that the company's net profit attributable to shareholders of Q1 in 2018 and 2019 was 3,631,700 yuan and 8,661.4 thousand yuan respectively, and operating income was 151,196,600 yuan and 5,075,300 yuan respectively. 615.644 million yuan and 18.8617 million yuan, accounting for 40.92% and 37.16% of the current operating income.

Previously, in May 2018, the Chengdu Pioneer completed a new round of financing with a valuation of 2.15 billion yuan (after investment), such as Juci Limited and Dinghui New Trend Changxing. It is understood that after the proceeds from the IPO issuance and listing, after deducting the issuance expenses, the investment in the new molecular design, construction and application platform construction project and the new drug research and development center construction project will be carried out in the order of priority.

xx值得注意的是,招股说明书还指出,近年来,由于制药行业政策鼓励创新药物和制药企业的研发投入,国内CRO公司发展迅速,逐步形成了一些规模化,综合性的医药研发服务企业。如药明康德,康龙华城,以及一些技术独特的小型CRO公司,这些公司在布局早期药物筛选阶段后,已开始尝试进入DNA编码化合物库技术领域。

此外,近年来,跨国制药公司已部署DEL技术并增加了投资。外国竞争对手如Nuevolution(丹麦)和X-Chem(美国)在DEL技术领域都处于DEL库的规模和合作数量。各方面都有一定程度的发展,成都飞行员将面临来自国际资深竞争对手和国内CRO公司的竞争。

RVo4cVk58hffc7

新技术尚未萌芽,未来可以预期吗?

值得一提的是,尽管成都先锋在过去七年中已经发展和积累,但该公司通过自主创新研究开发了10多个处于临床前开发不同阶段的新药项目,但其HDAC。 I/IIb项目仍处于临床阶段I.

然而,根据广州标点的数据,随着药物开发变得更加困难和成本增加,全球医药研发投入继续增加。从2010年到2018年,全球生物医学研究和开发成本从1090亿美元增加到1366亿美元,而研发成本包括药物研究成本和药物开发成本。其中,药品开发成本从741亿美元增加到929亿美元,占整体研发成本的68%。据估计,到2020年,全球生物医药研发费用将达到1506亿美元,其中药物开发费用将达到1024亿美元,年均增长率约为5%。成都先锋在招股说明书中表示,药品研发外包服务公司有更好的市场前景和更大的增长空间。 2018年,中国药品服务外包服务业市场规模达到678亿元,同比增长20%以上。国内医药市场需求持续增长。在制药业分割加剧,市场许可制度实施,药品研发外包服务业全球化趋势进一步加强等因素的影响下,国内药品研发外包服务市场有望出现到2022年将达到1402.1亿元,2019 - 2022年平均增长率预计在20%左右。

广州日报全媒体作家:苏赞

图片:来自上海证券交易所官方网站官方网站栏目

日期归档
凯发电游官网app 版权所有© www.towerarrays.com 技术支持:凯发电游官网app | 网站地图